This review finds that BPC 157 uniquely heals not only individual tendon, ligament, and muscle injuries but also the junctions between them — areas where traditional growth factors show limited or no efficacy.
Junctional healing without carriersBPC 157 is the only agent reviewed that healed osteotendinous, myotendinous, and muscle-to-bone junctions without requiring scaffolds, carriers, or tissue engineering
What the researchers found
The review's central finding is a clear distinction between growth factors and BPC 157 in musculoskeletal healing:
**Growth factors** (PDGF, TGF-β1, IGF-1, FGF, VEGF, BMPs): When delivered locally with carriers, they improve tendon, ligament, and muscle healing individually. However, some (PDGF, TGF-β1, IGF-1) fail in muscle lesions specifically, and all show limited or no efficacy in healing the junctions — osteotendinous (tendon-to-bone), myotendinous (muscle-to-tendon), and muscle-to-bone connections.
**BPC 157**: Acts alone without any carrier, combining beneficial effects on tendon, ligament, and muscle injuries simultaneously with junctional healing. In rat studies, it was effective across multiple routes — intraperitoneal injection, oral (intragastric or drinking water), and topical cream application.
Why it matters
Musculoskeletal junction injuries — where tendons meet bone, muscles meet tendons, or muscles attach to bone — are among the most challenging injuries in sports medicine and orthopedics. Current treatments often focus on individual tissues and neglect these critical transition zones. If BPC 157's animal study results translate to humans, it could address a major unmet need in musculoskeletal healing, particularly for complex injuries involving multiple tissue types.
How the study worked
This is a systematic review comparing the evidence for PRP, growth factors, and BPC 157 in treating musculoskeletal and junctional injuries. The authors evaluated preclinical and clinical evidence for each agent's efficacy when administered directly (locally or systemically), focusing on the ability to heal tissues and their interconnected junctions without relying on complex scaffolds or tissue engineering constructs.
What this study cannot tell us
The BPC 157 evidence reviewed is overwhelmingly from rat studies, with no large-scale human clinical trials reported. Much of the BPC 157 research comes from a single research group (Sikiric et al.), raising questions about independent replication. The review's framing strongly favors BPC 157 over growth factors. Direct head-to-head comparisons between BPC 157 and growth factors in identical injury models are limited. The cytoprotection mechanism proposed is conceptual and not fully defined at the molecular level.
How to read the evidence
This is a systematic review of predominantly preclinical (rat) studies. While the breadth of evidence for BPC 157 is extensive, it remains largely confined to animal models from a limited number of research groups. The absence of large human clinical trials and the potential for publication bias limit the evidence grade.
When this study was published
Published in 2026, this is a current comprehensive review. However, it draws on BPC 157 animal studies spanning several decades. The lack of progression to large-scale human trials despite extensive preclinical data is notable.
The bigger picture
This review positions BPC 157 within the broader landscape of regenerative musculoskeletal therapies. While PRP and growth factor treatments have become mainstream in sports medicine and orthopedics, their inability to heal junctional tissues represents a significant limitation. BPC 157's proposed advantage — working at junctions without carriers or scaffolds — could be paradigm-changing if confirmed in human trials. However, the peptide remains largely in the preclinical stage, and its cytoprotective mechanism is still being elucidated.
Questions still open
- When will randomized controlled trials in humans test BPC 157 for musculoskeletal injuries?
- Can independent research groups replicate the broad efficacy findings reported by the primary BPC 157 research group?
- What is the precise molecular mechanism by which BPC 157 promotes junctional healing where growth factors fail?
Common questions
What is BPC 157 and where does it come from?
Why are junction injuries so hard to heal?
Read the original research
Tendon, Ligament, and Muscle Injury, Osteotendinous, Myotendinous, and Muscle-to-Bone Junction Therapy Perspectives with Growth Factors and Stable Gastric Pentadecapeptide BPC 157-A Review.
Pharmaceuticals (Basel, Switzerland), 19(2)
Citation
Matek, Danijel; Matek, Irena; Japjec, Mladen; Matek, Mirta; Prenc, Jakov; Staresinic, Borna; Staresinic, Eva; Prtoric, Andreja; Sikiric, Suncana; Beketic Oreskovic, Lidija; Oreskovic, Ivana; Strbe, Sanja; Kordic, Mario; Tvrdeic, Ante; Seiwerth, Sven; Sikiric, Predrag; Boban Blagaic, Alenka; Skrtic, Anita; Bojanic, Ivan; Dobric, Ivan; Staresinic, Mario. (2026). Tendon, Ligament, and Muscle Injury, Osteotendinous, Myotendinous, and Muscle-to-Bone Junction Therapy Perspectives with Growth Factors and Stable Gastric Pentadecapeptide BPC 157-A Review.. Pharmaceuticals (Basel, Switzerland), 19(2). https://doi.org/10.3390/ph19020309